RGEN · Repligen Corp
$166.83
-0.66 (-0.39%)
At close · Aug 14
Market Cap
$9.42B
Shares
56.44M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$738.26M
+16.4%
FY2025
Net Income
$48.89M
+291.6%
FY2025
Gross Margin
52.32%
+9pp
FY2025
Operating Margin
7.47%
+13pp
FY2025
Diluted EPS
$0.86
+287%
FY2025
Operating Cash Flow
$117.42M
-33.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $785.1M | $738.26M | $634.44MG | $632.36M | $801.54M | $670.53M | $366.26M | $270.25M | $194.03M | $141.24M | $104.54M | $83.54M | $63.55M | $68.17M | $62.27M | $27.29M | |
| $364.9M | $352.01M | $359.79M | $353.92M | $345.83M | $279.28M | $156.63M | $119.1M | $86.53M | $67.05M | $47.12M | $35.25M | $28.02M | $22.48M | $24.96M | $5.58M | |
| $420.2M | $386.25M | $274.65M | $278.44M | $455.71M | $391.25M | $209.63M | $151.15M | $107.5M | $74.19M | $57.42M | $48.29M | $35.53M | $45.69M | $37.31M | $21.71M | |
| — | 52.32% | 43.29% | 44.03% | 56.85% | 58.35% | 57.23% | 55.93% | 55.4% | 52.53% | 54.93% | 57.8% | 55.9% | 67.02% | 59.92% | 79.55% | |
| $56.97M | $54.18M | $43.2M | $42.72M | $43.94M | $34.27M | $20.18M | $19.45M | $15.82M | $8.67M | $7.36M | $5.74M | $5.61M | $7.34M | $10.49M | $12.53M | |
| $302.05M | $290.51M | $263.37M | $218.58M | $215.83M | $183.87M | $119.62M | $95.61M | $65.69M | $51.51M | $30.85M | $24.7M | $17.15M | $12.7M | $13.23M | $8.02M | |
| $39M | $39.1M | $34.7M | $31.6M | $27.1M | $22.1M | $16.1M | $13.6M | $10.6M | $6.2M | $2.1M | $1.6M | $1.43M | $1.02M | $1.02M | $179K | |
| — | $78.75M | $69.67M | $68.56M | $50.99M | $38.45M | $27.07M | $20.87M | $15.78M | $10.51M | $5.33M | $4.59M | $4.02M | $3.11M | $3.51M | $1.67M | |
| $720.49M | $683.09M | $669.55M | $584.66M | $576.87M | $503.29M | $296.44M | $234.16M | $168.04M | $127.23M | $88.57M | $69.77M | $52.86M | $45.3M | $51.18M | $27.67M | |
| $64.61M | $55.17M | -$35.11M | $47.7M | $224.67M | $167.25M | $69.82M | $36.08M | $25.99M | $14.01M | $15.97M | $13.76M | $10.69M | $22.87M | $11.08M | -$374.07K | |
| — | 7.47% | -5.53% | 7.54% | 28.03% | 24.94% | 19.06% | 13.35% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.8% | -1.37% | |
| — | $133.91M | $34.56M | $116.26M | $275.66M | $205.7M | $96.89M | $56.95M | $41.77M | $24.51M | $21.31M | $18.36M | $14.71M | $25.99M | $14.59M | $1.3M | |
| $22.15M | $21.51M | $20.73M | $1.95M | $1.16M | $11.28M | $10.77M | $9.29M | $6.71M | $6.44M | $3.77M | $32K | $50K | $50K | $56.71K | $26.17K | |
| -$12.46M | $7.22M | $8.08M | $9M | -$5.53M | -$13.71M | -$10.61M | -$9.93M | -$4.55M | -$6.76M | -$4.28M | -$445K | $188K | -$110K | $26.4K | — | |
| — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| $52.15M | $62.38M | -$27.04M | $56.71M | $219.14M | $153.54M | $59.22M | $26.15M | $21.44M | $7.25M | $11.69M | $13.42M | $11.14M | $23.01M | $11.27M | -$1.6M | |
| $10.61M | $13.49M | -$1.52M | $21.11M | $33.18M | $25.25M | -$709K | $4.74M | $4.82M | -$21.11M | $11K | $4.08M | $2.97M | $6.92M | -$2.88M | $15.77K | |
| $41.54M | $48.89M | -$25.51M | $35.6M | $185.96M | $128.29M | $59.93M | $21.41M | $16.62M | $28.35M | $11.68M | $9.35M | $8.17M | $16.09M | $14.16M | -$1.61M | |
| — | 6.62% | -4.02% | 5.63% | 23.2% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -5.91% | |
| $23.47M | $98.9M | -$40.24M | $32.18M | $168.45M | $109.32M | $77.04M | $18.28M | $11.09M | $35.74M | $6.5M | $6.55M | $399K | $16.18M | $15.95M | — | |
| USD/shares | — | $0.87 | -$0.46 | $0.64 | $3.35 | $2.33 | $1.14 | $0.44 | $0.38 | $0.74 | $0.35 | $0.28 | $0.25 | $0.51 | $0.46 | $0.00 |
| USD/shares | — | $0.86 | -$0.46G | $0.63 | $3.24 | $2.24 | $1.11 | $0.44 | $0.37 | $0.72 | $0.34 | $0.28 | $0.25 | $0.50 | $0.45 | $0.00 |
| shares | — | 56.23K | 55.94K | 55.72K | 55.46K | 55.02K | 52.55K | 48.34M | 43.77M | 38.23M | 33.57K | 32.88M | 32.5M | 31.67M | 30.91M | 30.78M |
| shares | — | 56.56K | 55.94K | 56.38K | 57.46K | 57.26K | 53.89K | 49.21M | 45.47M | 39.15M | 34.1K | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $14.39M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
11.66×
Peer median 3.28×
EV/EBIT
141.71×
Peer median 31.00×
P/E (TTM)
—
Peer median 34.47×
Peer medians compare against the 25 similar-size Medical Instruments & Supplies companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Filtration Products | $402,792,000 | $372,963,000 | $341,379,000 | $495,930,000 | $403,505,000 | $174,851,000 | $119,464,000 | $90,586,000 |
| Chromatography Products | $153,176,000 | $122,810,000 | $126,629,000 | $131,680,000 | $91,037,000 | $70,677,000 | $60,662,000 | $45,326,000 |
| Proteins Products | $97,435,000 | $74,425,000 | $103,463,000 | $114,320,000 | $123,707,000 | $83,317,000 | $69,004,000 | $54,375,000 |
| Process Analytics Products | $81,237,000 | $59,301,000 | $56,820,000 | $53,512,000 | $48,019,000 | $33,346,000 | $16,405,000 | — |
| Other Products | $3,320,000 | $4,679,000 | $3,688,000 | $5,741,000 | $4,051,000 | $3,945,000 | $4,562,000 | $3,604,000 |
| Royalty | $296,000 | $261,000 | $383,000 | $353,000 | $215,000 | $124,000 | $148,000 | $141,000 |
Key facts
CIK
730272
CUSIP
759916109
13F (30d)
461 filings
436 filers
Visit website
Investor relations